Tobam Invests $301,000 in Insulet Corporation $PODD

Tobam bought a new stake in Insulet Corporation (NASDAQ:PODD) during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor bought 957 shares of the medical instruments supplier’s stock, valued at approximately $301,000.

A number of other institutional investors also recently bought and sold shares of PODD. Sequoia Financial Advisors LLC boosted its position in shares of Insulet by 2.3% during the 2nd quarter. Sequoia Financial Advisors LLC now owns 2,017 shares of the medical instruments supplier’s stock worth $634,000 after acquiring an additional 45 shares in the last quarter. Nissay Asset Management Corp Japan ADV boosted its holdings in Insulet by 0.6% in the first quarter. Nissay Asset Management Corp Japan ADV now owns 8,462 shares of the medical instruments supplier’s stock valued at $2,222,000 after purchasing an additional 48 shares in the last quarter. Mather Group LLC. increased its stake in Insulet by 4.4% in the second quarter. Mather Group LLC. now owns 1,147 shares of the medical instruments supplier’s stock valued at $360,000 after purchasing an additional 48 shares during the last quarter. Brooklyn Investment Group raised its holdings in Insulet by 7.0% during the first quarter. Brooklyn Investment Group now owns 795 shares of the medical instruments supplier’s stock worth $209,000 after purchasing an additional 52 shares in the last quarter. Finally, Cooper Financial Group raised its holdings in Insulet by 5.7% during the first quarter. Cooper Financial Group now owns 1,079 shares of the medical instruments supplier’s stock worth $283,000 after purchasing an additional 58 shares in the last quarter.

Insulet Stock Performance

Shares of PODD opened at $326.28 on Wednesday. The stock has a market capitalization of $22.97 billion, a P/E ratio of 99.17, a P/E/G ratio of 2.64 and a beta of 1.39. The company has a debt-to-equity ratio of 0.64, a quick ratio of 1.81 and a current ratio of 2.26. Insulet Corporation has a 1 year low of $230.05 and a 1 year high of $353.50. The company’s fifty day moving average is $324.30 and its two-hundred day moving average is $311.20.

Insulet (NASDAQ:PODD) last issued its earnings results on Thursday, November 6th. The medical instruments supplier reported $1.24 earnings per share for the quarter, beating the consensus estimate of $1.13 by $0.11. The business had revenue of $521.70 million for the quarter, compared to the consensus estimate of $678.70 million. Insulet had a net margin of 10.01% and a return on equity of 23.78%. The business’s quarterly revenue was up 29.9% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $1.08 earnings per share. Insulet has set its FY 2025 guidance at EPS. Q4 2025 guidance at EPS. On average, sell-side analysts predict that Insulet Corporation will post 3.92 earnings per share for the current year.

Analyst Upgrades and Downgrades

PODD has been the topic of several research reports. BTIG Research reaffirmed a “buy” rating and set a $370.00 price objective on shares of Insulet in a report on Thursday, November 6th. Stifel Nicolaus began coverage on Insulet in a research report on Tuesday, October 21st. They set a “buy” rating and a $370.00 price target on the stock. Oppenheimer increased their price objective on Insulet from $324.00 to $365.00 and gave the company an “outperform” rating in a report on Monday, September 8th. Barclays raised their target price on shares of Insulet from $300.00 to $301.00 and gave the stock an “equal weight” rating in a research report on Wednesday, November 5th. Finally, UBS Group upped their price target on shares of Insulet from $320.00 to $355.00 and gave the company a “neutral” rating in a research report on Friday, November 7th. One equities research analyst has rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and three have given a Hold rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $374.10.

Insider Buying and Selling

In other news, SVP Laetitia Cousin sold 797 shares of the firm’s stock in a transaction that occurred on Monday, September 8th. The stock was sold at an average price of $348.81, for a total value of $278,001.57. Following the completion of the sale, the senior vice president directly owned 3,890 shares of the company’s stock, valued at $1,356,870.90. This trade represents a 17.00% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, SVP Prem Singh sold 687 shares of the company’s stock in a transaction on Monday, September 8th. The stock was sold at an average price of $347.49, for a total value of $238,725.63. Following the transaction, the senior vice president directly owned 3,456 shares in the company, valued at $1,200,925.44. This represents a 16.58% decrease in their position. The disclosure for this sale is available in the SEC filing. Corporate insiders own 0.39% of the company’s stock.

Insulet Company Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.